I typically do not use mepolizumab for "vasculitic" EGPA --> recent ACR/VF guidelines agreed Interesting study @TerrierBen suggests benefit regardless of ANCA, BVAS, VDI Have others been using in this context or seen similar? #ACR22 @RheumNow #ACRBest #1075 https://t.co/C6isdSn2eI

Are we really treating Psoriatic disease if we only address active disease domains and T2T? #ACR22 https://t.co/D3F5EzLfeP https://t.co/TO3GyZA6Lb

#ACR22 Abstr#1654 Press Release #lupus. A cohort study using case-crossover design showed that HCQ dose =<5mg/kg actual body weight OR <400mg/day were associated with increased risk of severe #SLE flare requiring hospitalisation. Need to review Guidelines on HCQ dose @RheumNow https://t.co/5mMh7g6wcA

Toxic granules in blood vessels may damage vasculature and cause fibrosis around vessels. ‘Occult vascular disease occurs in #scleroderma, don’t forget about it’ says Wigley at Hench Memorial Lecture #ACR22 ⁦@RheumNow⁩ ⁦@ACRheum⁩ insights by a humble #SSc leader 🙏🏻 https://t.co/M82p6DwZ6Q

AURORA 2 data VOC-treated pts w/ pure and mixed Class V lupus nephritis saw reductions in UPCR that occurred faster than in those treated with MMF and low-dose steroids alone. Abs 0355 #ACR22 @RheumNow https://t.co/eHVLDCcti8 https://t.co/jbuiOSqqsa

Targeting MRI remission in RA, specifically targeting osteitis, did not confer benefit over clinical T2T over 2 years. Maybe our clinical examination is not so bad afterall @steverheum_hall @RheumNow ABST0890 #ACR22 https://t.co/8nUjWQONyk https://t.co/xGzZNLiJ7U

Meng MA of risk of tapering MTX from combo with bDMARD/tsDMARD in RA in remission. RR 0.90 (95% CI 0.84, 0.97) for maintaining remission over maximum 18 months. Authors conclude little risk to stopping - I disagree 10% is >0. @RheumNow #ACR22 Abstr#0916 https://t.co/9lJXdeVmpg https://t.co/CEV29Mc8uW

Leng et al. 52 week results tocilizumab biosimilar vs originator in RA. Shocker, it's the same. @RheumNow #ACR22 Abstr#0917 https://t.co/5JAoGBRzUi https://t.co/7zCUNcdzbp

Proliferative LN assoc'd w/ higher risk of IFTA progression, suggesting that glomerular damage is one of the major drivers of IFTA progression in SLE. Abs 0319 #ACR22 @RheumNow https://t.co/CgdXhDBk3e https://t.co/AOZ1DnH6Sk

Package insert for avacopan has a lot of monitoring requirements, including liver risk, but that seems to be relatively small (2 events per 100 pt-yrs vs pred). Other risks actually favorable as compared to pred How are others monitoring LFTs? #ACR22 @RheumNow #1077 https://t.co/VFHCpkQMWN

Kim et al. KOBIO study retention rates b/tsDMARDs in RA-ILD. Lower than in RA without ILD. Smoking (OR 5.2) steroids (OR 0.3) influence. JAKi>tocilizumab>abatacept>TNFi @RheumNow #ACR22 Abstr#0920 https://t.co/ht7IFP7VJe https://t.co/Ul93kcdP5N